Clinical Trial Update: Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial of mirabegron in children aged 3 to less than 18 with neurogenic detrusor overactivity completed; results were posted in May 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity

Drugs mentioned

• Mirabegron (mirabegron)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Neurogenic Detrusor Overactivity | Phase 3 | Status: COMPLETED | Results posted: 2020-05-12